
Bristol Myers Squibb has scooped up the sole rights to the interleukin-12 (IL-12) immunotherapy programme of Massachusetts-based biotech Dragonfly Therapeutics, …
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ

